Display options
Cite
Roger C, Louart B, Elotmani L, et al. An international survey on aminoglycoside practices in critically ill patients: the AMINO III study. Ann Intensive Care. 2021;11(1):49doi: 10.1186/s13613-021-00834-4.
Roger, C., Louart, B., Elotmani, L., Barton, G., Escobar, L., Koulenti, D., Lipman, J., Leone, M., Muller, L., Boutin, C., Amour, J., Banakh, I., Cousson, J., Bourenne, J., Constantin, J. M., Albanese, J., Roberts, J. A., Lefrant, J. Y. (2021). An international survey on aminoglycoside practices in critically ill patients: the AMINO III study. Annals of intensive care, 11(1), 49. https://doi.org/10.1186/s13613-021-00834-4
Roger, Claire, et al. "An international survey on aminoglycoside practices in critically ill patients: the AMINO III study." Annals of intensive care vol. 11,1 (2021): 49. doi: https://doi.org/10.1186/s13613-021-00834-4
Roger C, Louart B, Elotmani L, Barton G, Escobar L, Koulenti D, Lipman J, Leone M, Muller L, Boutin C, Amour J, Banakh I, Cousson J, Bourenne J, Constantin JM, Albanese J, Roberts JA, Lefrant JY. An international survey on aminoglycoside practices in critically ill patients: the AMINO III study. Ann Intensive Care. 2021 Mar 19;11(1):49. doi: 10.1186/s13613-021-00834-4. PMID: 33740157; PMCID: PMC7979853.
Copy Download .nbib Format: NLM
Share it on

Ann Intensive Care. 2021 Mar 19;11(1):49. doi: 10.1186/s13613-021-00834-4.

An international survey on aminoglycoside practices in critically ill patients: the AMINO III study.

Annals of intensive care

Claire Roger, Benjamin Louart, Loubna Elotmani, Greg Barton, Leslie Escobar, Despoina Koulenti, Jeffrey Lipman, Marc Leone, Laurent Muller, Caroline Boutin, Julien Amour, Iouri Banakh, Joel Cousson, Jeremy Bourenne, Jean-Michel Constantin, Jacques Albanese, Jason A Roberts, Jean-Yves Lefrant,

Affiliations

  1. Department of Intensive Care Medicine, Division of Anesthesiology, Intensive Care, Pain and Emergency Medicine, Nîmes University Hospital, Place du Professeur Robert Debré, 30 029, Nîmes cedex 9, France. [email protected].
  2. Equipe D, Caractéristiques Féminines Des Interfaces Vasculaires (IMAGINE), Faculté de Médecine, Univ Montpellier, 2992, Montpellier, France. [email protected].
  3. Department of Intensive Care Medicine, Division of Anesthesiology, Intensive Care, Pain and Emergency Medicine, Nîmes University Hospital, Place du Professeur Robert Debré, 30 029, Nîmes cedex 9, France.
  4. Equipe D, Caractéristiques Féminines Des Interfaces Vasculaires (IMAGINE), Faculté de Médecine, Univ Montpellier, 2992, Montpellier, France.
  5. St Helens and Knowsley Hospitals NHS Trust, Liverpool, UK.
  6. Faculty of Medicine, Universidad de Chile, Santiago, Chile.
  7. The University of Queensland Centre for Clinical Research, The University of Queensland, Brisbane, Australia.
  8. Second Critical Care Department, Attikon University Hospital, Athens, Greece.
  9. Department of Intensive Care Medicine, Royal Brisbane and Women's Hospital, Brisbane, Australia.
  10. Department of Anesthesiology and Intensive Care Medicine, University Hospital of Marseille, Marseille, France.
  11. Institute of Perfusion, Critical Care Medicine and Anesthesiology in Cardiac Surgery (IPRA), Hôpital Privé Jacques Cartier, Massy, France.
  12. Frankston Hospital, Frankston, VIC, Australia.
  13. Department of Anesthesiology and Intensive Care Medicine, University Hospital of Reims, Reims, France.
  14. Department of Emergency and Intensive Care Medicine, University Hospital of Marseille, Hôpital de La Timone, Marseille, France.
  15. Department of Anesthesiology and Intensive Care Medicine, University Hospital of Clermont-Ferrand, Clermont-Ferrand, France.
  16. Department of Anesthesiology and Intensive Care Medicine, University Hospital of Marseille, Hôpital de La Conception, Marseille, France.
  17. Pharmacy Department, Royal Brisbane and Women's Hospital, Brisbane, Australia.

PMID: 33740157 PMCID: PMC7979853 DOI: 10.1186/s13613-021-00834-4

Abstract

BACKGROUND: While aminoglycosides (AG) have been used for decades, debate remains on their optimal dosing strategy. We investigated the international practices of AG usage specifically regarding dosing and therapeutic drug monitoring (TDM) in critically ill patients. We conducted a prospective, multicentre, observational, cohort study in 59 intensive-care units (ICUs) in 5 countries enrolling all ICU patients receiving AG therapy for septic shock.

RESULTS: We enrolled 931 septic ICU patients [mean ± standard deviation, age 63 ± 15 years, female 364 (39%), median (IQR) SAPS II 51 (38-65)] receiving AG as part of empirical (761, 84%) or directed (147, 16%) therapy. The AG used was amikacin in 614 (66%), gentamicin in 303 (33%), and tobramycin in 14 (1%) patients. The median (IQR) duration of therapy was 2 (1-3) days, the number of doses was 2 (1-2), the median dose was 25 ± 6, 6 ± 2, and 6 ± 2 mg/kg for amikacin, gentamicin, and tobramycin respectively, and the median dosing interval was 26 (23.5-43.5) h. TDM of C

CONCLUSION: Short courses of high AG doses are mainly used in ICU patients with septic shock, although wide variability in AG usage is reported. We could show no correlation between PK/PD target attainment and clinical outcome. Efforts to optimize the first AG dose remain necessary. Trial registration Clinical Trials, NCT02850029, registered on 29th July 2016, retrospectively registered, https://www.clinicaltrials.gov.

Keywords: Aminoglycoside; Antibiotics; ICU; PK/PD; Therapeutic drug monitoring

References

  1. Biometrics. 1986 Mar;42(1):121-30 - PubMed
  2. J Glob Antimicrob Resist. 2018 Mar;12:90-95 - PubMed
  3. Lancet. 2007 Oct 20;370(9596):1453-7 - PubMed
  4. Expert Rev Clin Pharmacol. 2016 Jul;9(7):961-79 - PubMed
  5. Antimicrob Agents Chemother. 2011 Jun;55(6):2528-31 - PubMed
  6. Chest. 1999 Feb;115(2):462-74 - PubMed
  7. J Infect Dis. 1984 Mar;149(3):443-8 - PubMed
  8. J Antimicrob Chemother. 2016 Oct;71(10):2754-9 - PubMed
  9. Am J Med. 1984 Oct;77(4):657-62 - PubMed
  10. Crit Care Med. 2009 Mar;37(3):840-51; quiz 859 - PubMed
  11. JAMA. 2016 Feb 23;315(8):801-10 - PubMed
  12. Int J Antimicrob Agents. 2015 Jul;46(1):21-7 - PubMed
  13. Crit Care Clin. 2011 Jan;27(1):107-21 - PubMed
  14. Curr Opin Crit Care. 2007 Oct;13(5):592-7 - PubMed
  15. Therapie. 2011 Jan-Feb;66(1):39-44 - PubMed
  16. Antimicrob Agents Chemother. 1999 Jul;43(7):1549-55 - PubMed
  17. Anaesth Intensive Care. 2002 Apr;30(2):134-44 - PubMed
  18. Intensive Care Med. 2015 Jul;41(7):1181-96 - PubMed
  19. Int J Antimicrob Agents. 2011 Aug;38(2):146-51 - PubMed
  20. Ther Drug Monit. 2008 Dec;30(6):674-81 - PubMed
  21. Ther Drug Monit. 1999 Feb;21(1):63-73 - PubMed
  22. Med Mal Infect. 2012 Jul;42(7):301-8 - PubMed
  23. Crit Care. 2007;11(2):R31 - PubMed
  24. Stat Med. 2009 Jan 30;28(2):221-39 - PubMed
  25. Crit Care Med. 2013 Feb;41(2):580-637 - PubMed
  26. J Antimicrob Chemother. 2016 Jan;71(1):208-12 - PubMed
  27. Clin Pharm. 1986 Apr;5(4):319-24 - PubMed
  28. Crit Care. 2010;14(2):R53 - PubMed
  29. Crit Care Med. 2006 Jun;34(6):1589-96 - PubMed
  30. Crit Care Med. 2003 Feb;31(2):462-7 - PubMed
  31. Anaesth Crit Care Pain Med. 2020 Dec;39(6):883-885 - PubMed
  32. J Biomed Inform. 2019 Jul;95:103208 - PubMed
  33. Intensive Care Med. 2014 Jul;40(7):998-1005 - PubMed
  34. JAMA. 2012 Jun 13;307(22):2390-9 - PubMed
  35. J Infect Dis. 1987 Jan;155(1):93-9 - PubMed
  36. Clin Microbiol Infect. 2010 Aug;16(8):1258-63 - PubMed
  37. Crit Care Med. 2017 Mar;45(3):486-552 - PubMed
  38. Fundam Clin Pharmacol. 2018 Dec;32(6):669-677 - PubMed
  39. Crit Care. 2013 Jul 25;17(4):R165 - PubMed
  40. Intensive Care Med. 2017 Jun;43(6):816-828 - PubMed

Publication Types